The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.

Mazur, GM of LillyDirect, breaks down the platform’s new partnership with Walmart and its implications for the pharma ...

In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli ...

Robert Armstrong There has been a wild and hectic series of M&A deals in the pharmaceuticals industry. We are now headed for ...

Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system, today announced the appointment of Eduardo ...

United States President Donald Trump’s planned tariffs on pharmaceuticals have disrupted the industry. Here’s a timeline of ...

By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent comments from Pfizer 's (NYSE: PFE) CEO, Albert Bourla, suggest it could become ...

Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals ...

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded ...